Latest News

The year in review – 2023

 

The year 2023 was marked by a number of anniversaries and what may be a turning point in the approach to MS research and clinical practice. Read More

TOPICS:

NfL a marker of microglial activation

 

Elevated levels of serum neurofilament-light chain (NfL), a marker of axonal damage, are an indicator of increased microglial activation in the brain, according to a positron emission tomography (PET) study in Finland (Saraste et al. J Neurol Neurosurg Psychiatry 2023;94:698-706). Read More

Biomarkers after stopping treatment may identify at-risk MS patients

 

Increasing levels of neurofilament-light chain (NfL) and glial fibrillary acidic protein (GFAP) after drug discontinuation may identify previously stable MS patients at risk of new disease activity, according to Comprehensive Longitudinal Investigation of MS at the Brigham and Women’s Hospital (CLIMB) investigators (Bose et al. Neurol Neuroimmunol Neuroinflamm 2023;10:e200167; free full text at www.ncbi.nlm.nih.gov/pmc/articles/PMC10574823/pdf/NXI-2023-000383.pdf ). Read More

Exploring the lung-brain axis in MS

 

An emerging concept in MS research is the role of the lung microbiome in promoting disease severity, with preliminary evidence showing that pulmonary micro-organisms can regulate autoimmunity in the central nervous system (reviewed in Chen et al. Int J Mol Sci 2023;24:2170). Read More

TOPICS: